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SUMMARY
Orally administered fungal vaccines show promise for the prevention of infectious dis-
eases. Edible mushrooms are deemed appropriate hosts to produce oral vaccines due to 
their low production cost and low risk of gene contamination. However, their low expression 
level of antigens has limited the potential development of oral vaccines using mushrooms. 
The low expression level might result from impurity of the transgenic mycelia since dikary-
otic mycelia are commonly used as transformation materials. In this study, stable transgenic 
hepatitis B virus surface antigen (HBsAg) in Flammulina velutipes transformants was obtained 
by Agrobacterium-mediated transformation, followed by fruiting and basidiospore mating. 
The formation of HBsAg was detected by western blot analysis. The expression levels of 
HBsAg in transgenic F. velutipes fruiting bodies were (129.3±15.1), (110.9±1.7) and (161.1±8.5) 
ng/g total soluble protein. However, the values may be underestimated due to incomplete 
protein extraction. Two of the four pigs in the experimental group produced positive an-
ti-HBsAg-specific IgG after being fed the HBsAg transgenic F. velutipes fruiting bodies for 20 
weeks, while no anti-HBsAg antibody was detected in the control group. One of the posi-
tive pigs had HBsAg titres of 5.36 and 14.9 mIU/mL in weeks 10 and 14, respectively, but ex-
pression faded thereafter. The other positive pig displayed HBsAg titres of 9.75, 17.86 and 
39.87 mIU/mL in weeks 14, 18 and 20, respectively. The successful immunogenicity in pigs 
fed transgenic F. velutipes fruiting bodies demonstrated the potential of using the fungus 
as an oral vaccine.
Key words: Agrobacterium-mediated transformation, Flammulina velutipes, hepatitis B, mat-
ing, oral vaccine
INTRODUCTION
Although vaccinations have saved millions of lives from infectious diseases, full imple-
mentation of global vaccination remains a challenge due to the relatively high costs of con-
ventional vaccinations incurred by mass production, refrigeration and transportation, as 
well as by training and compensating personnel for their administration. To overcome these 
problems, many efforts have been devoted to the development of novel and cost-effective 
vaccination procedures and technologies. In addition to injected vaccines, oral administra-
tion of either raw materials or extracts from transgenic plants, spirulina or yeasts has been 
reported to stimulate systemic and mucosal immunity (1).
Oral vaccines are known to stimulate multiple types of immunity, including mucosal 
and humoral immunity (2). Plant-based oral vaccines were first proposed two decades ago 
(3). The use of transgenic fruits and vegetables for the expression of recombinant protein 
antigens as oral vaccines has become an attractive topic in plant molecular farming (1,4). 
For example, many efforts have been made to develop hepatitis B oral vaccines by express-
ing hepatitis B virus surface antigen (HBsAg) in transgenic plants such as tobacco, tomato, 
potato, banana, tomatillo and rice (5-12). In addition to plants, edible mushrooms are also 
appropriate hosts for the development of oral vaccines (13). Using transgenic mushrooms 
as oral vaccines has all the advantages of a plant-based system coupled with unique ben-
efits, such as complete duplication, fast growth, scaled-up production under controlled 
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conditions and less gene contamination. A previous study 
demonstrated the effectiveness of extracts of mycelia derived 
from edible mushrooms as adjuvants for intranasal influenza 
vaccines (14). Pérez-Martínez et al. (15) provided a comprehen-
sive review on the use of Pleurotus as carrier of oral subunit vac-
cines. While mushroom-based oral vaccines seem promising, 
the low expression level of antigens and the instability of the 
transformants limit the development of mushroom molecular 
farming. Previously, we demonstrated that heterologous pro-
tein expression in the enoki mushroom Flammulina velutipes 
is notably enhanced by using 2A peptide-mediated cleavage 
to co-express multiple copies of a single gene (16). Using this 
polycistronic expression strategy, enterovirus 71 virus-like par-
ticles were successfully produced in transgenic F. velutipes (17).
Mating and fruiting body formation are sexual stages in 
the life cycle of basidiomycete fungi and lead to karyogamy, 
meiosis and basidiospore formation. F. velutipes is a heteroth-
allic basidiomycete fungus whose life cycle is characterized 
by haploid and diploid stages (18). F. velutipes has a tetrapo-
lar mating type system that generates basidiospores with four 
possible mating types. After germination, the haploid spores 
develop into monokaryotic mycelia with AxBx, AxBy, AyBx or 
AyBy mating types. Although single mating types have been 
known to produce fruiting bodies under severe stress, most 
fruiting requires the plasmogamy of two genetically different 
monokaryotic mycelia, AxBx/AyBy or AxBy/AyBx, to form the 
dikaryotic mycelia that consist of two nuclei in a cell and the 
structure of clamp connection (19). The generation of trans-
genic mushrooms usually involves Agrobacterium-mediated 
transformation using modified mycelial pellets, followed by 
the selection of transformants under appropriate pressures 
(17). Transformants are selected if the foreign gene is inserted 
into the chromosomal DNA in at least one nucleus of the my-
celia. Consequently, the expression level and stability of heter-
ologous genes are reduced if the transformants contain both 
transgenic and non-transgenic cells. Therefore, it is crucial to 
obtain transformants containing the transgene in all nuclei.
In this study, stable HBsAg transgenic F. velutipes trans-
formants were obtained by Agrobacterium-mediated trans-
formation, followed by fruiting and basidiospore mating. We 
demonstrated that specific immunogenicity was detected in 
pigs after feeding HBsAg transgenic F. velutipes fruiting bodies 
for a period of time.
MATERIALS AND METHODS
Strains and media
Flammulina velutipes BCRC 930110, a patented strain de-
posited at the Bioresource Collection and Research Centre 
(Hsinchu, Taiwan), was grown and maintained on complete 
yeast medium (CYM) agar or in broth containing 0.2 % tryp-
tone (BD Bioscience, Sparks, MD, USA), 0.2 % yeast extract 
(Bio Basic, Amherst, NY, USA), 1 % maltose (Sigma-Aldrich, 
Merck, St. Louis, MO, USA), and 2 % glucose (Bio Basic) at 25 °C. 
Escherichia coli DH5α (Gibco BRL, Life Technologies, Grand 
Island, NY, USA), which was used for DNA manipulation and 
plasmid conservation, was grown in Luria-Bertani (LB) medi-
um (Sigma-Aldrich, Merck) at 37 °C. Agrobacterium tumefa-
ciens strain LBA4404, kindly provided by Dr Yee-Yung Charng, 
Agricultural Biotechnology Research Centre, Academia Sinica 
(Taipei, Taiwan), was used for transformations and was grown 
in LB medium at 28 °C.
Plasmid construction
A promoter region of the Agaricus bisporus glyceralde-
hyde-3-phosphate dehydrogenase (Agpd) gene was ampli-
fied from the genome of A. bisporus by using primers Agpd-f 
(5’-TTAAGAGGTCCGCAAGTAGATTGA-3’) and Agpd-r (5’-ATGT-
GTGTTGTTCGAATAGCGG-3’). The plasmid pGEM-Agpd was 
constructed by cloning the Agpd promoter into a pGEM-T 
Easy vector (Promega, Madison, WI, USA). The E. coli hygromy-
cin B phosphotransferase (hpt) gene with cauliflower mosa-
ic virus (CaMV) 35S terminator was amplified from pCAMBIA 
1300 (Cambia, Canberra, Australia) using primers SpeI-Hpt-f 
(5´-ACTAGTATGAAAAAGCCTGAACTCACC-3´) and PstI-CaMV 
35S terminator-r (5´-TTACACAATAATTCAACAGACGTCGG-3´). 
Then, the amplified fragment was cloned into a pGEM-Agpd 
by restriction enzymes SpeI and PstI. The backbone plasmid 
p0390-AH was constructed by introducing the hpt and CaMV 
35S terminator gene driven by Agpd promoter into the pCAM-
BIA0390 (p0390) vector (CAMBIA) by using restriction enzymes 
NcoI and PstI. The F. velutipes gpd (Fgpd) promoter was ampli-
fied from the F. velutipes genome by using primers NcoI-Fgpd-f 
(5’-CCATGGGCATTACTTCGCTCTA-3’) and KpnI-Fgpd-r (5’-CG-
GTACCTTGTAGATGAGGAG-3’). The plasmid pGEM-Fgpd was 
constructed by cloning the Fgpd promoter into a pGEM-T Easy 
vector. The codon usage of hepatitis B virus surface antigen 
(HBsAg) derived from plasmid pRc/CMV-HBs(S) (Aldevron, Far-
go, ND, USA) was modified according to the codon bias of F. 
velutipes, and an endoplasmic reticulum (ER) retention sig-
nal (HDEL) was fused to the C terminus of HBsAg protein to 
improve its expression. The gene of HBsAg was amplified by 
primers KpnI-HB-f (5’-GGTACCGATGGAGAACATCACAT-3’) and 
BstEII-HB-r (5’-GGTCACCTTACAGTTCATCATGACTAGCAA-3’) 
and cloned into a pGEM-Fgpd by restriction enzymes KpnI 
and BstEII. The construct carrying the gene encoding HBsAg 
(accession number MG717400) driven by the F. velutipes gpd 
promoter was cut from pGEM-Fgpd by restriction enzymes 
NcoI and BstEII inserted into p0390-AH, and the resulting plas-
mid was designated as p0390-AH-FmHB. A map of the plasmid 
constructs is shown in Fig. 1.
Transformation procedure
Agrobacterium-mediated transformation (AMT) was per-
formed as described by Chen et al. (20) with minor modifica-
tions. The p0390 or p0390-AH or p0390-AH-FmHB constructs 
were introduced into A. tumefaciens by electroporation (ECM 
630; BTX, San Diego, CA, USA). The A. tumefaciens strains har-
bouring the target plasmids were cultivated in LB medium 
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containing 50 μg/mL of kanamycin (MDBio Inc., Taipei, Tai-
wan) for 24 h at 28 °C, with shaking at 220 rpm, in an incubator 
(model S-300R; FIRSTEK, New Taipei City, Taiwan). The strains 
were then mixed with modified mycelial pellets (MMPs) of 
F. velutipes for 6 h at 23 °C in an induction medium contain-
ing 11.8 mM dipotassium phosphate, 10.7 mM monopotas-
sium phosphate, 2 mM magnesium sulfate, 0.6 mM calcium 
chloride, 9 μM iron(II) sulfate, 43.7 mM 2-(N-morpholino)- 
-ethanesulfonic acid (MES; pH=5.3), 200 µM acetosyringone 
(all from Sigma-Aldrich, Merck), 2.5 mM sodium chloride, 3.8 
mM ammonium sulfate, 0.18 % glucose (all from Bio Basic), 
and 0.5 % (m/V) glycerol (Riedel-de Haën; Honeywell, Mor-
ris, NJ, USA). After incubation, the MMPs were transferred to 
fresh induction medium agar plates and incubated at 23 °C 
for 3-6 days. Then, the treated MMPs were washed with ster-
ile water five times to remove bacteria, transferred to selec-
tive agar plates containing 30 μg/mL hygromycin B (Thermo 
Fisher Scientific, San Jose, CA, USA) and 200 mM cefotaxime 
(MDBio Inc.) and incubated at 25 °C for 2-3 weeks until hygro-
mycin B-resistant mycelia of F. velutipes appeared.
PCR analysis
F. velutipes transformants grown on selective agar plates 
were subsequently screened via PCR analysis to confirm the 
integration of HBsAg gene into the genomes. The HBsAg gene 
fragment was amplified by 96-well thermal cycler (Veriti™ 
9902; Applied Biosystems, Foster City, CA, USA) with prim-
ers HBsAg-f (5´-GAAGATCTATGGAGAACATCACATCC-3´) and 
HBsAg-r (5´-GTCGACGGGTCACCTTACAGTTCATCATGA-3´). 
Genomic DNA was extracted from four-week-old mycelia 
that were grown in CYM broth with 30 μg/mL hygromycin 
B, using the CTAB-mini DNA extraction method with minor 
modifications (21). The residual RNA in the isolated DNA was 
removed by treatment with DNase-free RNase A (GMbiolab 
Co., Ltd., Taipei, Taiwan).
Mycelium staining
Monokaryotic or dikaryotic mycelia on slides were fixed 
with 37 % formaldehyde (Sigma-Aldrich, Merck) for 2 min at 
room temperature. Samples were then rinsed twice with ster-
ile distilled water before incubation for 5 min at room tem-
perature with 1 μg/mL 4',6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich, Merck). The slides were observed by a fluo-
rescence microscope (Eclipse E600; Nikon, Kanagawa, Japan) 
fitted with a Nikon UV-2A filter (330-380 nm excitation filter, 
400 nm dichroic filter, and 420 nm barrier filter).
Fruiting and mating of transformants
The F. velutipes transformants were stabilized via mating. 
The fruiting body development procedure was described 
previously (22). Capped polypropylene bottles containing 70 
% sawdust and 30 % rice bran were purchased from Wanshen 
farm (Changhua, Taiwan), autoclaved for 1 h, then inoculated 
with mycelial plugs and incubated at 23 °C for approx. 3 to 4 
weeks. After the vegetative mycelia had grown throughout 
the substrate, fruiting was induced by water addition, air ex-
posure, and temperature change from 25 to 8 °C. The condi-
tions were kept humid during the fruiting period by watering 
every other day with sterile distilled water. The basidiospores 
were collected in a sealed plate (9-cm Petri dishes) from the 
mature fruiting bodies and separated by resuspending them 
in sterile water. The suspension was then spread on CYM agar 
plates containing 30 μg/mL hygromycin B to form monokar-
yotic mycelia which were verified by DAPI staining. Mating 
was conducted by placing two mycelial plugs on the same 
CYM agar plate for 2 weeks at 23 °C. Successful mating was 
also confirmed by the formation of clamp connections and 
the presence of two nuclei in a cell. Three dikaryotic trans-
formants were randomly picked for further analysis.
Western blot analysis
For western blot analysis of HBsAg, the fruiting bodies of 
the F. velutipes transformants and of wild-type controls were 
collected and ground in liquid nitrogen with a mortar and 
pestle. A total of 40 mg of sample powder was mixed on ice 
for 1 h with 0.5 mL of protein extraction buffer containing 
50 mM potassium phosphate (pH=7.4; Sigma-Aldrich, Merck), 
0.1 % Triton X-100 (J.T.Baker, Avantor, Radnor, PA, USA), 300 
mM sodium chloride (Bio Basic), and 1 mM phenylmethane 
sulfonyl fluoride (PMSF; Sigma-Aldrich, Merck). The total sol-
uble protein (TSP) was obtained by centrifugation (13 000×g 
Fig. 1. A map of the plasmid construction: Agpd=the gpd promoter 
derived from Agaricus bisporus, Fgpd=the gpd promoter derived from 
Flammulina velutipes, mHBsAg=modified hepatitis B virus surface 
antigen after codon optimization, kan=kanamycin-resistant gene 
from Escherichia coli, hpt=hygromycin B phosphotransferase gene 
derived from E. coli, NOS 3’ UTR=nopaline synthase 3’ UTR, CaMV 
3’ UTR=cauliflower mosaic virus 35S terminator, pVS1 sta and pVS1 
rep=stability and replication regions of vector pVS1, respectively, 
pBR322 ori=origin of replication of vector pBR322, PstI, SpeI, NcoI, 
KpnI and BstEII=restriction enzymes isolated from Providencia 
stuartii, Sphaerotilus sp., Nocardia corallina, Klebsiella pneumonia and 
Bacillus stearothermophilus, respectively, LB=left border, RB=right 
border. Numbers in brackets represent the position of the restriction 
sites 
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for 30 min at 4 °C) using Thermo Scientific Sorvall® Legend 
Mach 1.6 R tabletop centrifuge (Thermo Fisher Scientific), 
boiled for 20 min with sample buffer containing 50 mM Tris- 
-HCl (pH=7.4; Bio-Rad, Hercules, CA, USA), 2 % sodium do-
decyl sulfate (SDS), 0.1 % bromophenol blue, 10 % glycerol, 
400 mM dithiothreitol (DTT) and 800 mM 2-mercaptoethanol 
(all from Sigma-Aldrich, Merck), and separated by 12 % sodi-
um dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). The protein samples were transferred via a Trans-Blot® 
electrophoretic transfer cell (Bio-Rad) to a polyvinylidene dif-
luoride (PVDF) membrane (Millipore, Bedford, MA, USA). Pro-
tein was detected using a mouse monoclonal anti-HBsAg an-
tibody (ab9193; Abcam, Taipei, Taiwan) and a goat anti-mouse 
IgG antibody-conjugated alkaline phosphatase (ab97020; 
Abcam) in a reaction with 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium (BCIP/NBT) (PerkinElmer, Foster 
City, CA, USA) as described by the manufacturers.
HBsAg quantification
HBsAg was detected using the SURASE B-96 kit (Gen-
eral Biologicals Corporation, Taipei, Taiwan) according to 
the manufacturer’s instructions. Plate wells coated with an-
ti-HBsAg antibody were incubated with 50 μL of TSP and an-
ti-HBsAg antibody-conjugated peroxidase for 90 min at 37 
°C. Each assay was repeated in triplicate for each plate. After 
the incubation, the plate wells were washed six times with 
phosphate buffer (provided in the kit), then 100 μL of the 
TMB One Component HRP microwell substrate (BioFX Labo-
ratories Inc., Owings Mills, MD, USA) was added to each well, 
and the plates were incubated for 30 min at 37 °C. The reac-
tion was stopped by the addition of 2 M sulfuric acid (pro-
vided in the kit), and the absorbance at 450 nm of each well 
was measured using a 96-well plate reader (VERSAmax™; Mo-
lecular Devices, LLC, San Jose, CA, USA). Protein concentra-
tions were determined using the Pierce™ BCA Protein Assay 
Kit (Pierce Biotechnology, Thermo Fisher Scientific, Rockford, 
IL, USA). The SURASE B-96 quantitative standard panel is in-
cluded with each assay.
Animal tests
The animal tests were conducted at Animal Technolo-
gy Laboratories, Agriculture Technology Research Institute 
(Chunan, Taiwan). Specific pathogen-free (SPF) pigs, four 
males and three females, three weeks old, 19 kg of average 
body mass, were provided by the Cheng-Yu Pig Farm (Hsin-
chu City, Taiwan). The fruiting bodies of transgenic F. veluti-
pes with the highest HBsAg content were used for the animal 
tests. Four pigs, two males and two females, in the exper-
imental group were each fed with 9 g dry transgenic F. ve-
lutipes fruiting body powder every 3 days for 6 consecutive 
weeks, followed by feeding once a week for another 14 con-
secutive weeks. Another three pigs fed with wild-type F. ve-
lutipes were used as the control group. The fruiting body pow-
der was mixed with 2 kg fodder composed of corn, soybean 
and rice bran (Cheng-Yu Pig Farm), and left in the cage for 24 
h or until all food was consumed. Regular fodder was used 
throughout the experiment. Starting from the sixth week, 
blood samples were collected periodically for antibody assay.
Measurement of anti-HBsAg antibodies
HBsAg antibodies were detected with Elecsys anti-HBs 
(Roche, Basel, Switzerland) electrochemiluminescence im-
munoassay according to the manufacturer’s instructions us-
ing Modular E170 immunology analyzer (Roche). Anti-HBsAg 
antibodies in the sample, biotinylated HBsAg, and HBsAg la-
belled with a ruthenium complex reacted to form a sandwich 
complex. After the addition of streptavidin-coated micropar-
ticles, the complex bound to the solid phase via interaction of 
biotin and streptavidin. The reaction mixture was aspirated 
into the measuring cell where the microparticles were mag-
netically captured onto the surface of the electrode. Applica-
tion of a voltage to the electrode induced chemiluminescent 
emission which was measured by Modular E170 immunol-
ogy analyzer (Roche). Results were determined via a calibra-
tion curve which was instrument-specifically generated by 
2-point calibration and a master curve provided via the rea-
gent barcode, calculated in milli-international units per vol-
ume (mIU/mL), and reported as positive when the value was 
more than 10 mIU/mL.
Statistical analysis
Least significant difference (LSD at p=0.05) test was used 
to identify significant differences of the expression level 




A. tumefaciens containing p0390, p0390-AH or p0390- 
-AH-FmHB was co-cultivated with F. velutipes MMPs in in-
duction medium for 5–7 days and then transferred to se-
lective agar plates containing 30 μg/mL hygromycin B. The 
plasmids p0390 and p0390-AH were used as negative and 
positive control, respectively. As shown in Fig. 2, hygromy-
cin B-resistant mycelia appeared approx. 2-4 weeks after 
the transfer to the selective agar plates; however, F. velutipes 
MMPs co-cultivated with A. tumefaciens carrying the empty 
vector p0390 failed to grow. To confirm the stability of the 
putative transformants carrying the plasmid p0390-AH-Fm-
HB, they were subcultured three times on the agar plates un-
der selection pressure to ensure that the hygromycin B resist-
ance gene and the HBsAg gene were stably expressed in F. 
velutipes. Even though the transformants can stably grow on 
the selective agar plates, their mycelia might be composed 
of both transgenic and non-transgenic cells. To resolve this 
problem, mushroom fruiting and basidiospore mating were 
conducted.
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Transformant fruiting and mating
Two putative transformants were selected as the paren-
tal strains for fruiting. The fruiting bodies of transformants 1 
and 2 were cultivated and the basidiospores were collected. 
The basidiospores were separated by spreading them onto 
CYM agar plates containing 30 μg/mL hygromycin B to form 
monokaryotic mycelia. PCR analysis served to investigate the 
presence of the HBsAg gene. Fig. 3 illustrates that HBsAg gene 
was stably maintained in the parental (Fig. 3a) and the filial 
generation (Fig. 3b) of dikaryotic transformants, and in the 
monokaryotic mycelium transformants derived from paren-
tal generation (Fig. 3c). The successful mating was checked by 
the clamp connection and by compatible growth of two mo-
nokaryotic mycelial plugs. No clamp connections were ob-
served in the monokaryotic mycelia (Fig. 4a). Mating was con-
ducted by placing two monokaryotic mycelial plugs on the 
same CYM agar plate containing 30 μg/mL hygromycin B and 
incubating at 23 °C for 3 weeks. The successful mating was 
confirmed by compatible growth between two monokary-
otic mycelial plugs (Fig. 4b) and clamp connections (Fig. 4c). 
These results show that both nuclei in each pure cell of the 
filial dikaryotic mycelia contained the target gene. The dikar-
yotic mycelia containing the HBsAg gene remained stable af-
ter repeated subculture (data not shown). The fruiting bod-
ies of the stable dikaryotic mycelia were cultivated for further 
HBsAg analysis and for the animal tests.
HBsAg quantification and qualification via ELISA and 
western blot analysis
The western blot analysis of three HBsAg transgenic F. ve-
lutipes fruiting bodies is shown in Fig. 5. Immunoblotting with 
the monoclonal anti-HBsAg antibody detected a band at 25.4 
kDa in the positive control (without the endoplasmic reticu-
lum (ER) retention sequence) and a band at 26.1 kDa in the 
transformants, while no signal was observed in wild-type F. 
velutipes. The HBsAg expression level in the fruiting bodies of 
these three transformants was determined by ELISA (Fig. 6). 
Fig. 2. The process of Agrobacterium tumefaciens-mediated trans-
formation: a) Flammulina velutipes MMPs co-cultured with A. tume-
faciens transformants (p0390, p0390-AH and p0390-AH-FmHB) on 
induction medium, b) co-cultured MMPs transferred onto selection 
medium with 30 μg/mL hygromycin B. WT=wild-type F. velutipes
Fig. 3. PCR analysis of putative transformants: a) the parental gener-
ation of HBsAg Flammulina velutipes dikaryotic transformants, b) the 
filial generation of HBsAg F. velutipes dikaryotic transformants, and 
c) the monokaryotic mycelium transformants derived from parental 
generation. Lanes 1 and 2=the parental generation of HBsAg F. veluti-
pes dikaryotic transformants, lanes A, B and C=the filial generation 
of HBsAg F. velutipes dikaryotic transformants, lanes A1, A2, B1, B2, C1 
and C2=the mating type of monokaryotic transformants of A, B and C, 
lane WT=wild-type F. velutipes, lane P=positive control using plasmid 
p0390-AH-FmHB, lane N=negative control, and lane M=marker
Fig. 4. The mating process of Flammulina velutipes transformants: 
a) microphotographs of monokaryotic mycelia of transformants 
stained by DAPI, b) morphology of the filial generation of HBsAg F. 
velutipes transformants after mating, and c) microphotographs of fil-
ial generation of HBsAg F. velutipes transformants stained by DAPI. 
Lanes A, B and C=the filial generation of HBsAg F. velutipes dikaryotic 
transformants, lanes A1, A2, B1, B2, C1 and C2=the mating type of mo-
nokaryotic transformants of A, B and C, white arrow=clamp connec-
tion, red arrow=nucleus
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Previous research has expressed HBsAg in edible plant 
tissues, including lettuce leaves (23), cherry tomatillos and 
tomatoes (7), at less than 0.000001 % of fresh mass, while in 
potato tubers it was up to 0.002 % of fresh mass (5). The low an-
tigen expression level might be attributed to molecular biology 
mechanisms such as codon bias, improper mRNA splicing and 
post-translational modification, or to impure transgenic myce-
lia. In this study, the codons of HBsAg were optimized by check-
ing the cDNA sequences via reversed transcription PCR, thus 
eliminating the potential for improper mRNA splicing. Since the 
stability of HBsAg virus-like particles relies on disulphide bond 
formation in the ER (24), an ER retention signal, HDEL, was con-
structed to ensure the retention of HBsAg in the ER and increase 
the likelihood of forming the correct structure. In addition, pure 
HBsAg transgenic F. velutipes mycelia were obtained via a mat-
ing scheme. The low expression level may be a result of incom-
plete protein extraction and weak antibody recognition since 
the antigenic domain presented on hepatitis B virus envelope 
is a conformational rather than a linear epitope (25). The de-
velopment of more efficient HBsAg extraction and detection 
methods from transgenic F. velutipes fruiting bodies is required.
Oral immunogenicity of HBsAg was stimulated by 
transgenic F. velutipes
The immune response to the HBsAg transgenic F. velutipes 
fruiting bodies in pigs is shown in Table 1. No anti-HBsAg an-
tibody was detected in the control group throughout the ex-
periment. The blood sample collected from male pig 15903 in 
the experimental group displayed an antibody response val-
ue of 5.36 mIU/mL in week 10, which is below the positive re-
sponse value (10 mIU/mL). The HBsAg-specific IgG level in this 
pig reached a maximum of 14.9 mIU/mL in week 14 and then 
decreased thereafter. Female pig 17215 had HBsAg levels of 
9.75, 17.86 and 39.87 mIU/mL in weeks 14, 18 and 20, respec-
tively. The other two pigs in the experimental group did not 
produce detectable antibodies. These results provide solid ev-
idence that a primary anti-HBsAg immune response can be 


























Fig. 5. Expression of HBsAg in Flammulina velutipes transformants: 
a) the western blot analysis of three HBsAg transgenic F. velutipes 
fruiting body immunoblotting with the monoclonal anti-HBsAg an-
tibody, b) immunoblotting with the monoclonal anti-GPD antibody. 
GPD=glyceraldehyde-3-phosphate dehydrogenase. Lane WT=wild 
type, lanes A, B and C=the filial generation of HBsAg F. velutipes trans-
formants, lane P=positive control, a commercial HBsAg (226 amino 
acids, 25.4 kDa); the HBsAg expressed in transformants is 232 amino 
acids, 26.1 kDa, and lane M=marker
Fig. 6. HBsAg quantification of fruiting bodies for wild-type and trans-
genic Flammulina velutipes. WT=wild type, A, B and C=the filial gener-
ation of HBsAg F. velutipes transformants, TSP=total soluble protein. 
The HBsAg assays were repeated three times. The error bars indicate 
the standard deviation. Expression level among transformants A, B 
and C is not significantly different (p>0.05)





6 8 10 14 18 20
N(antibody)/(mIU/mL)
Control
16113 (F) 2.00 2.00 2.00 2.00 2.00 2.00
17202 (M) 2.00 2.00 2.00 2.00 2.00 2.00
17204 (M) 2.00 2.00 2.00 2.00 2.00 2.00
Experiment
16114 (F) 2.00 2.00 2.00 2.00 2.00 2.00
17215 (F) 2.00 2.00 2.00 9.75 17.86 39.87
15903 (M) 2.00 2.00 5.36 14.90 2.00 2.00
17308 (M) 2.00 2.00 2.00 2.00 2.00 2.00
mIU=milli-international units, F=female, M=male
Due to severe weather conditions no blood was collected in the 12th and 16th week
The HBsAg expression level of transformants A, B and C was 
(129.3±15.1), (110.9±1.7) and (161.1±8.5) ng/g TSP, respectively. 
Transformant C was further used for the large-scale production 
of fruiting bodies for animal tests. The results indicate that sta-
ble HBsAg transgenic F. velutipes fruiting bodies were gener-
ated using monokaryotic mycelium selection and the basidi-
ospore mating.
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Several studies have suggested that increased immuno-
genicity of HBsAg using oral administration via transgenic po-
tatoes and tomatoes usually requires an adjuvant, such as chol-
era toxin (CT). Richter et al. (5) reported that feeding mice with 
5 µg HBsAg expressed in potato tuber and 10 µg CT prompt-
ed a serum response peaking at approx. 70 mIU/mL. In the ab-
sence of adjuvant, primary immunization with 40 µg oral dos-
es of potato-expressed antigen did not induce a response (6), 
but otherwise with 60 µg oral doses antigen prompted an an-
tibody response up to 170 mIU/mL (26). In this study, a positive 
response was obtained by feeding transgenic F. velutipes fruit-
ing bodies without CT, indicating that the mushroom polysac-
charides might serve the role of an adjuvant. This observation 
is consistent with the report of Ichinohe et al. (14), who demon-
strated the effectiveness of mycelial extracts derived from edi-
ble mushrooms as adjuvants for an intranasal influenza vaccine.
CONCLUSION
In this study, we obtained stable HBsAg transgenic F. veluti-
pes dikaryotic mycelia via a mating scheme and confirmed that 
the production of anti-HBsAg antibodies was stimulated in pigs 
by feeding them F. velutipes fruiting bodies, demonstrating the 
potential of the application of F. velutipes in oral vaccines. This 
is the first report to show that the immunogenicity in pigs can 
be achieved by feeding them transgenic HBsAg mushroom.
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